Siemens Healthineers has deployed its first mobile stroke unit in the U.S., with an ambulance equipped with its own CT ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

In an effort to maximize the earnings potential of its plaque psoriasis cream, Danish dermatology biotech MC2 Therapeutics ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...

Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels.

Instead, Stealth submitted a new drug application (NDA) seeking approval of elamipretide and the FDA issued its ...

A Dutch neuromodulation developer has raised $60 million to complete the development of its minimally invasive implant for ...

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

The FDA and Stealth look set to relitigate the debate, with the biotech planning to file for approval once again. Stealth has ...